JP2012502047A - 心房細動を治療する方法 - Google Patents

心房細動を治療する方法 Download PDF

Info

Publication number
JP2012502047A
JP2012502047A JP2011526201A JP2011526201A JP2012502047A JP 2012502047 A JP2012502047 A JP 2012502047A JP 2011526201 A JP2011526201 A JP 2011526201A JP 2011526201 A JP2011526201 A JP 2011526201A JP 2012502047 A JP2012502047 A JP 2012502047A
Authority
JP
Japan
Prior art keywords
ranolazine
amiodarone
atrial
administered
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502047A5 (OSRAM
Inventor
チャールズ アンツェレビッチ,
アレキサンダー バラシュニコフ,
ジョン シュライオック,
スリダーラン ラジャマニ,
ルイス ベラーディネリ,
Original Assignee
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ, インコーポレイテッド filed Critical ギリアード サイエンシーズ, インコーポレイテッド
Publication of JP2012502047A publication Critical patent/JP2012502047A/ja
Publication of JP2012502047A5 publication Critical patent/JP2012502047A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011526201A 2008-09-04 2009-09-03 心房細動を治療する方法 Pending JP2012502047A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9435908P 2008-09-04 2008-09-04
US61/094,359 2008-09-04
US10877608P 2008-10-27 2008-10-27
US61/108,776 2008-10-27
PCT/US2009/055924 WO2010028173A2 (en) 2008-09-04 2009-09-03 Method of treating atrial fibrillation

Publications (2)

Publication Number Publication Date
JP2012502047A true JP2012502047A (ja) 2012-01-26
JP2012502047A5 JP2012502047A5 (OSRAM) 2012-10-18

Family

ID=41421639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526201A Pending JP2012502047A (ja) 2008-09-04 2009-09-03 心房細動を治療する方法

Country Status (5)

Country Link
US (1) US20100056536A1 (OSRAM)
EP (1) EP2337559A2 (OSRAM)
JP (1) JP2012502047A (OSRAM)
CA (1) CA2735653A1 (OSRAM)
WO (1) WO2010028173A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ, インコーポレイテッド Cns障害の治療のためのラノラジン
CN102725290B (zh) 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
MX2016008077A (es) 2013-12-19 2016-10-12 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ionico.
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528393A (ja) * 2002-04-04 2005-09-22 シーブイ・セラピューティクス・インコーポレイテッド 不整脈の治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AU2498100A (en) * 1999-01-11 2000-08-01 Board Of Regents Of The University And Community College System Of Nevada, The Use of an amiodarone compound as antifungal agent
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528393A (ja) * 2002-04-04 2005-09-22 シーブイ・セラピューティクス・インコーポレイテッド 不整脈の治療法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6013060420; PACE Vol.31, No.6, 200806, p.765-768 *
JPN6013060423; Prog. Med. Vol.27, suppl.2, 2007, p.2760-2764 *
JPN6013060425; Prog. Med. Vol.27, suppl.2, 2007, p.2729-2732 *
JPN6013060429; Japanese Journal of Electrocardiology Vol.27, No.3, 2007 *
JPN6013060432; Annals of the New York Academy of Sciences Vol.1123, 200803, p.105-112 *
JPN6013060435; J. Cardiovasc. Pharmacol. Vol.52, No.2, 200808, p.121-128 *
JPN6013060437; 臨床と研究 Vol.83, No.10, 2006, p.1455-1458 *
JPN6013060439; Prog. Med. Vol.25, suppl.1, 2005, p.1561-1565 *

Also Published As

Publication number Publication date
WO2010028173A3 (en) 2010-11-04
WO2010028173A2 (en) 2010-03-11
EP2337559A2 (en) 2011-06-29
US20100056536A1 (en) 2010-03-04
CA2735653A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
JP2012502047A (ja) 心房細動を治療する方法
AU2010339753B2 (en) Method of treating atrial fibrillation
TWI519298B (zh) 決奈達隆(dronedarone)於製備用於預防心血管疾病住院或死亡之藥劑之用途
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
JP2018528251A (ja) 心房細動の予防及び治療のためのドフェチリドとメキシレチンの組合せ
Advani et al. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol
CA2727210A1 (en) Dronedarone for the prevention of cardioversion
JP7137852B2 (ja) 9‐β‐D‐アラビノフラノシルヒポキサンチンによる不整脈治療
AU2014274638B2 (en) Method of treating atrial fibrillation
Schneeweiss et al. Ethmozine
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
HK1197535A (en) Method of treating atrial fibrillation
HK1170675B (en) Method of treating atrial fibrillation
HK1197535B (en) Method of treating atrial fibrillation
CN104363906A (zh) 去乙基胺碘酮组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141219